Champagne Reception
Hors d'oeuvres, drinks, and specialty stations
Champagne toast to the HBS Centennial

• Welcome by Wolfgang Klietmann, MD, OPM 12
  President-elect of HBS Health
  Conference Co-Chair, HBS Health Industry Conference
• Richard G. Hamermesh, MBA '71, DBA '76
  Professor of Management Practice
  HBS Faculty Chair, HBS Healthcare Initiative
• Health à la French Lifestyle, A Recipe for Life
  Mireille Guiliano
  Author, French Women Don’t Get Fat (free copies for attendees)
  Founder and former CEO, Clicquot, Inc.
  Book signing following talk
  
  

Friday, November 7
__________________________________________________________________

Badge Pick-Up (No onsite registration.)

Continental Breakfast

Healthcare at the Intersection of Medicine, Technology and Business
Opening Remarks and Introduction

• Wolfgang Klietmann, MD, OPM 12
  President-elect of HBS Health
  Conference Co-Chair, HBS Health Industry Conference

The interdisciplinary mixing of traditionally separate disciplines of knowledge and research is creative, but this convergence resulting in a cross-fertilization will even be of a new dimension. Are we facing a third industrial revolution in the era of the life sciences? America is still at the forefront of the next revolution in science, and medical technology. These convergent technologies will require new structures and business models for their development. The greatest challenge is for management to understand the multifactorial complexity and the scientific tools to avoid an information gap in this accelerating self-feeding process. Diagnostics, prevention, therapy, devices, pharmaceutical products are intimately intertwined with the progress in research and basic science. Are you ready to meet the challenge?

The Science Behind the Future of Medicine

• Phillip A. Sharp, PhD
  Institute Professor
  David H. Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology
  Nobel Laureate

Coffee Break/Networking

The Coming Collision: How Information Technology and Restless Consumers Will Wrest Health Care’s Future From Policymakers and Professionals

• David J. Brailer, MD, PhD
  Chairman, Health Evolution Partners
  Former National Coordinator for Health Information Technology
  US Department of Health and Human Services

Advances in information technology and shifting consumer preferences are driving fundamental changes in the way health care is organized, financed and delivered. Consumers are becoming more aware of their health, well-informed about their choices and options and shopping for the best care at the lowest prices. As a result, health care progress may not unfold in the ways called for in numerous white papers, commission reports and policy proposals. It may instead disrupt existing organizations and brands, shift market power and alter longstanding assumptions and practices among professionals, policymakers and other traditional health care overseers.

11:00 AM - 11:45 PM
Amphitheater

The Business of Genomics:  A Look Back and A Look Forward

• Tony L. White
  Chairman, President and CEO
  Applied Biosystems, Inc.

Tony White spent more than 25 years rising through the ranks at Baxter International and developing and selling products that monitored or managed, as much as possible, the symptoms of illness. He became CEO of Norwalk, CT-based Perkin Elmer in 1995, seeing the developing opportunity to apply the DNA analysis technologies of its Applied Biosystems unit to study—and perhaps eventually to treat—the root causes of disease. White’s talk will recount the high and low points of the business of genomics over the past 13 years. He'll take us from the heady days of supplying the Human Genome Project and creating Celera, challenger to the scientific establishment served by Applied Biosystems, to the lean years after the genomics bubble burst and NIH spending stalled. Then he will bring us to the present and beyond, when new tools for structural and functional biology are powering a more sophisticated understanding of gene regulation and genetic diversity, and when content developers like Celera are introducing molecular diagnostic tests for heart disease and cancer and other conditions—genetic tests that begin to validate the promise of the genomic revolution.  

Luncheon

Coffee Break/Networking

4:15 - 6:00 PM
Amphitheater

Saturday, November 8
_________________________________________________________________

8:30 AM - 12:00 PM
Second Floor Lounge

Roundtable Discussions

• Steven Wardell, MBA '00
  Roundtable Chair, HBS Health Industry Alumni Association
  
  Choose a roundtable according to your areas of interest, and discuss a specific healthcare topic over coffee, croissants and muffins. Click here for more on roundtables.

Medical Tourism and Telemedicine:
International Outsourcing: A Solution for Health Care Access and Cost Problems?

Medical travel is no longer for cosmetic surgery and spas. An estimated half-million Americans seek medical care each year abroad. This is a thriving $60 billion global business, with a growth rate of 20 percent according to Lancet. US insurers can save considerably by reimbursing much lower expenses for elective procedures overseas.

• Regina E. Herzlinger, DBA
  Nancy R. McPherson Professor of Business Administration
  Harvard Business School

Teleradiology: A Discipline That Pioneered the Digital Era of Telemedicine

• Paul E. Berger, MD
  CEO
  NightHawk Radiology Holdings, Inc.

Medical Travel Panel Discussion

• Moderator: Regina E. Herzlinger, DBA
  Nancy R. McPherson Professor of Business Administration
  Harvard Business School
  
• Vashil Bali
  CEO
  Wockhardt Hospitals
• David Boucher
  President and CEO
  Companion Global Healthcare, Inc., a wholly-owned
  subsidiary of BlueCross BlueShield of South Carolina
• Avery Comarow
  Senior Writer, U.S.News & World Report
• Ori Karev
  CEO
  UnitedHealth International

__________________________________________________________________
NEW FOR 2008
POST-CONFERENCE EVENT
Saturday, November 8

Unleashing Harvard Innovations: A showcase of Harvard University's top medical technology spin out companies

Open to all, free to Conference attendees. Separate registration. Click here.

Get a sneak preview of the top 10 new healthcare technology companies being spun out of Harvard University.

Sirtris Pharmaceuticals, Infinity Pharmaceuticals and Curis are together worth over $1 billion. What do they all have in common? They are all spin-outs from Harvard University. At a special event immediately after the annual conference, you can get a sneak preview of the next generation companies coming out of Harvard University’s labs. These new technologies span pharmaceuticals, medical devices, diagnostics and life science instruments. They come from the labs of some of the greatest scientific entrepreneurs of our generation such as George Whitesides and Stu Schrieber.

Harvard University has transformed its intellectual property management from a simple licensing office to a full fledged technology and entrepreneur development operation complete with its own incubator fund and entrepreneurship bootcamp for faculty. These startup companies, all based on breakthrough technology developed in the labs at Harvard University, are seeking people like you to be investors, board members, advisors and strategic partners in the healthcare industry. This is a unique opportunity for HBS Health members to be the first to see the future technologies of healthcare, and who knows, maybe find the next billion dollar deal.

The following companies will present in rapid-fire format with each company giving only a 5 minute presentation followed by breakout follow-up sessions:

1) A novel mechanism anticancer drug based on the natural product avrainvillamide, originally derived from a marine fungus (Prof. Andrew Myers)

2) An antibody screening technology that uses non-immortalized cells encapsulated in pico-liter droplets to find cells that produce antibodies of interest – finding significantly higher quantities of viable candidates, in very short times, at speeds of 1 Khz (Prof. David Weitz)

3) Broad spectrum antibiotics for new targets (Prof. Daniel Kahne)

4) CARS endoscopy for biomedicine – based on a microscope platform using coherent anti-Stokes Raman scattering (CARS), a technology which allows “chemical imaging” of biological samples without the need for staining – now the CARS technology is being transferred to a fiber optic endoscope platform for surgical (in-vivo) applications – to achieve “real-time” intra-operative histopathology. (Prof. Sunney Xie)

5) Novel anti-inflammatory molecule (LNFPIII) with broad therapeutic application – validated in animal models of psoriasis, type 1 diabetes (NOD), multiple sclerosis (EAE), colitis, transplant rejection (Prof. Donald Harn)

6) Enhanced MRI using hyperpolarized nanoparticles. Use of hyperpolarized, functionalized silicon nanoparticles produces high resolution images – the particles have long “relaxation” times allowing for “time lapse” imaging (Prof. Charlie Marcus)

7) Magneto-optic cell sorting – extremely cost effective, microfluidics based – aimed at MACS and FACS applications with potential of bed-side use for diagnostic and therapeutic applications (Prof. Mara Prentiss)

8) HDAC inhibitor portfolio – small molecule, isoform-specific HDAC inhibitors for the treatment of oncologic, inflammatory, and neurological disorders. (Prof. Stuart Schreiber)

9) Adaptable cell-based assay platform – new paradigm in drug development – rapidly customizable surface chemistries and microfluidics enable researchers to mimic a cell’s natural environment – providing real-life simulations for ADME-TOX studies (Prof. George Whitesides)

Co-hosted with the Harvard University Office of Technology Development